BioCentury | Aug 31, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
BioCentury | Aug 27, 2018
Financial News

Harbour BioMed raises $85M on heels of cancer deals

...the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd. (SZSE:002422). Mary Romeo GIC Private Limited Harbour Antibodies B.V. Harbour...
BioCentury | Aug 20, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
BioCentury | Sep 15, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired transgenic mouse technology company Harbour Antibodies B.V....
BioCentury | Sep 12, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired transgenic mouse technology company Harbour Antibodies B.V....
BioCentury | Dec 31, 2016
Finance

Seeking Harbour

...The scarcity value of the bispecific HCab transgenic mouse technology developed by Harbour Antibodies B.V. - coupled with...
...Advantech Capital and Legend Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired Harbour Antibodies...
...for an undisclosed amount of cash and stock. Atlas Venture was the sole investor in Harbour Antibodies’...
BioCentury | Dec 30, 2016
Company News

Harbour BioMed, Harbour Antibodies deal

...Harbour BioMed acquired Harbour Antibodies for an undisclosed upfront payment and equity investment. Harbour Antibodies’ H2L2 transgenic mouse...
...transgenic mouse platform generates heavy chain-only mAbs. Harbour BioMed was formed last year to acquire Harbour Antibodies...
...disclose financial terms. Harbour Antibodies B.V. , Rotterdam, the Netherlands Harbour BioMed , Shanghai, China Business: Cancer Alicia Parker Harbour Antibodies B.V. H2L2 Harbour...
BioCentury | Dec 20, 2016
Financial News

Harbour BioMed raises $50M, acquires Harbour Antibodies

...Harbour BioMed (Shanghai, China) closed a $50 million series A round and acquired antibody company Harbour Antibodies B.V....
...disclose details of the company's pipeline, but said it is developing therapeutic antibodies in oncology. Harbour Antibodies...
...can produce humanized bispecific antibodies from transgenic mice. Atlas Venture was the sole investor in Harbour Antibodies'...
BioCentury | Sep 30, 2013
Finance

Value ad(imab)

..."I think we should be able to do three per year for the foreseeable future." Harbour Antibodies B.V....
...Inc. (NASDAQ:BIIB), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Harbour Antibodies B.V....
BioCentury | Aug 5, 2013
Finance

mAbs for the masses

...mAbs for the masses Even though Harbour Antibodies B.V. is one of at least three biotechs seeking to...
Items per page:
1 - 10 of 17
BioCentury | Aug 31, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
BioCentury | Aug 27, 2018
Financial News

Harbour BioMed raises $85M on heels of cancer deals

...the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co. Ltd. (SZSE:002422). Mary Romeo GIC Private Limited Harbour Antibodies B.V. Harbour...
BioCentury | Aug 20, 2018
Company News

Harbour gets ex-China rights to Kelun's anti-PD-L1 mAb

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. granted Harbour BioMed (Shanghai, China) exclusive rights to anti-PD-L1 antibody A167 outside of the Greater China region. Kelun-Biotech is the small molecules and biologics-focused subsidiary of Sichuan Kelun Pharmaceutical Co....
BioCentury | Sep 15, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired transgenic mouse technology company Harbour Antibodies B.V....
BioCentury | Sep 12, 2017
Company News

Harbour gets Chinese rights to HanAll's biologics

...Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired transgenic mouse technology company Harbour Antibodies B.V....
BioCentury | Dec 31, 2016
Finance

Seeking Harbour

...The scarcity value of the bispecific HCab transgenic mouse technology developed by Harbour Antibodies B.V. - coupled with...
...Advantech Capital and Legend Capital, along with Harbour BioMed founders. In parallel, Harbour BioMed acquired Harbour Antibodies...
...for an undisclosed amount of cash and stock. Atlas Venture was the sole investor in Harbour Antibodies’...
BioCentury | Dec 30, 2016
Company News

Harbour BioMed, Harbour Antibodies deal

...Harbour BioMed acquired Harbour Antibodies for an undisclosed upfront payment and equity investment. Harbour Antibodies’ H2L2 transgenic mouse...
...transgenic mouse platform generates heavy chain-only mAbs. Harbour BioMed was formed last year to acquire Harbour Antibodies...
...disclose financial terms. Harbour Antibodies B.V. , Rotterdam, the Netherlands Harbour BioMed , Shanghai, China Business: Cancer Alicia Parker Harbour Antibodies B.V. H2L2 Harbour...
BioCentury | Dec 20, 2016
Financial News

Harbour BioMed raises $50M, acquires Harbour Antibodies

...Harbour BioMed (Shanghai, China) closed a $50 million series A round and acquired antibody company Harbour Antibodies B.V....
...disclose details of the company's pipeline, but said it is developing therapeutic antibodies in oncology. Harbour Antibodies...
...can produce humanized bispecific antibodies from transgenic mice. Atlas Venture was the sole investor in Harbour Antibodies'...
BioCentury | Sep 30, 2013
Finance

Value ad(imab)

..."I think we should be able to do three per year for the foreseeable future." Harbour Antibodies B.V....
...Inc. (NASDAQ:BIIB), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Harbour Antibodies B.V....
BioCentury | Aug 5, 2013
Finance

mAbs for the masses

...mAbs for the masses Even though Harbour Antibodies B.V. is one of at least three biotechs seeking to...
Items per page:
1 - 10 of 17